Biogen Inc.’s Stock Price Dips to $173.05, Down by 2.53%: Time to Buy or Bail?

Biogen Inc. (BIIB)

173.05 USD -4.50 (-2.53%) Volume: 1.42M

Biogen Inc.’s stock price stands at 173.05 USD, experiencing a trading session dip of -2.53% with a trading volume of 1.42M. Despite this, the company’s year-to-date performance showcases a positive trend with a rise of +16.11%, reinforcing its resilience in the volatile market.

Latest developments on Biogen Inc.

Biogen’s stock price has been on a rollercoaster ride recently, with analysts debating its growth potential. HSBC downgraded the stock due to royalty concerns, while also upgrading AbbVie. Despite this, Biogen received Health Canada authorization for Zurzuvae, a treatment for postpartum depression. The company’s innovative edge and strategic growth have led to conflicting analyst recommendations, with some seeing it as undervalued while others turn bearish. Eisai and Biogen’s LEQEMBI® being added to China’s commercial insurance innovative drug list further highlights the company’s global reach and impact. With Wells Fargo adjusting their price target and HSBC downgrading the stock, investors are closely watching to see how Biogen’s story unfolds in the market.

Biogen Inc. on Smartkarma

On Smartkarma, independent analysts have provided coverage on Biogen with a bullish sentiment. In a report titled “Primer: Biogen (BIIB UW) – Sep 2025,” analysts highlight Biogen’s transition from its declining multiple sclerosis franchise to a new portfolio focused on high-unmet-need neurological and rare diseases. The company’s future growth is dependent on the successful commercialization of new products like Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia, and Zurzuvae for postpartum depression. CEO Christopher Viehbacher is leading cost-saving initiatives to improve profitability and fund strategic collaborations and potential acquisitions to enhance Biogen’s pipeline.

A look at Biogen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Biogen Inc. has received a strong overall outlook based on the Smartkarma Smart Scores. With a high score in Momentum, the company is showing positive trends and strong performance in the market. Additionally, Biogen scores well in Value and Resilience, indicating a solid foundation and potential for long-term growth and stability.

However, the company’s scores in Dividend and Growth are lower, suggesting that Biogen may not be the most attractive option for investors seeking immediate returns or rapid expansion. Despite this, Biogen’s focus on developing therapies for neurology, oncology, and immunology positions it well in the healthcare industry, addressing a range of diseases and potentially providing opportunities for future growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma